Skip to main content

Table 1 Patient characteristics, clinical course and details of fluoropyrimidine rechallenge

From: Diagnosis and management of 5-fluorouracil (5-FU)-induced acute leukoencephalopathy: lessons learnt from a single-Centre case series

Case

Age (years)

Gender

Primary

Regimen

Cycle of onset

Day of onset

5-FU dosing

DPD testing

Naranjo score [9]

Fluoropyrimidine rechallenge (if any)

Follow-up (months)

1

22

Female

Rectum

m-FOLFOX6

1

2

Bolus: 400 mg/m2 D1

Infusion: 2400 mg/m2 over 48 h

Mutation in exon 2, 13 and 18 (heterozygous)

7

Capecitabine

25

2

30

Male

Rectum

5FU/LV

1

4

Bolus: 400 mg/m2 D1

Infusion: 2400 mg/m2 over 48 h

Wild

6

Capecitabine

23

3

34

Male

Rectum

5FU/LV

3

3

Bolus: 400 mg/m2 D1

Infusion: 2400 mg/m2 over 48 h

Wild

6

None

8

4

45

Female

Stomach

FLOT

1

2

Infusion:2600 mg/m2 over 24 h

Not done

6

Capecitabine

12

5

60

Male

Rectum

FOLFIRINOX

2

3

Bolus: not given

Infusion: 2400 mg/m2 over 48 h

Not done

6

Capecitabine

4